Allakos Inc. (ALLK)
NASDAQ: ALLK · Real-Time Price · USD
0.856
-0.055 (-5.99%)
At close: Jan 17, 2025, 4:00 PM
0.900
+0.044 (5.20%)
After-hours: Jan 17, 2025, 7:50 PM EST
Allakos Employees
Allakos had 131 employees as of December 31, 2023. The number of employees increased by 8 or 6.50% compared to the previous year.
Employees
131
Change (1Y)
8
Growth (1Y)
6.50%
Revenue / Employee
n/a
Profits / Employee
-$1,364,466
Market Cap
76.43M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ALLK News
- 4 weeks ago - Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - PRNewsWire
- 2 months ago - Allakos Runs Up Into A Near-Term Catalyst - Seeking Alpha
- 2 months ago - Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers - GlobeNewsWire
- 5 months ago - Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 7 months ago - The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate - Accesswire
- 7 months ago - The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Engage - Accesswire
- 7 months ago - Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile - GlobeNewsWire